Dexamethasone Placebo

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, David Palma, Peking Union Medical College Hospital

Conditions

Acute Respiratory Distress SyndromeChemotherapy-Induced Nausea and Vomiting (CINV)Interstitial Lung DiseaseLung Cancer

Phase 2

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

RecruitingNCT05986318

David PalmaInterstitial Lung Disease, Lung Cancer

Start: 2025-01-07End: 2032-12-31Target: 98Updated: 2026-03-09

Phase 3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

CompletedNCT01594749

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting (CINV)

Start: 2012-09-24End: 2014-11-03Updated: 2018-09-04

Unknown Phase

Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS

RecruitingNCT06387823

Peking Union Medical College HospitalAcute Respiratory Distress Syndrome

Start: 2024-04-15End: 2025-09-01Target: 300Updated: 2024-06-04

Related Papers

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

BMC Cancer2020-09-259 citations

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.

2018-05-288 citations

Abstract P6-11-11: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens

Cancer Research2018-02-152 citations

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies.

Journal of Clinical Oncology2017-05-20

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

2015-10-0855 citations

A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Journal of Clinical Oncology2015-05-203 citations

Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).

Journal of Clinical Oncology2014-05-20